References
- American Cancer Society. Key statistics for chronic myeloid leukemia. Atlanta (GA): American Cancer Society; [cited 2022 Aug 5]. Available from: https://www.cancer.org/cancer/chronic-myeloid-leukemia/about/statistics.html
- Hu Y, Li Q, Hou M, et al. Magnitude and temporal trend of the chronic myeloid leukemia: on the basis of the global burden of disease study 2019. J Clin Oncol Glob Oncol. 2021;7:1429–1441. doi: 10.1200/GO.21.00194.
- Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691–709. doi: 10.1002/ajh.25792.
- Mayo Clinic. Chronic myelogenous leukemia. USA: Mayo Clinic; [cited 2022 Aug 5]. Available from: https://www.mayoclinic.org/diseases-conditions/chronic-myelogenous-leukemia/symptoms-causes/syc-20352417
- American Cancer Society. Cancer facts & figures 2019. Atlanta (GA): American Cancer Society; 2019.
- National Cancer Institute. Cancer stat facts: leukemia—chronic myeloid leukemia (CML). Bethesda (MD): SEER; [cited 2022 Aug 5]. Available from: https://seer.cancer.gov/statfacts/html/cmyl.html
- National Health Service (NHS). Chronic myeloid leukaemia. UK: National Health Service; [cited 2023 Aug 5]. Available from: https://www.nhs.uk/conditions/chronic-myeloid-leukaemia/
- U.S. Food & Drug Administration. FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia. USA: Food & Drug Administration; [cited 2022 Aug 5]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia
- Pharmaceuticals and Medical Devices Agency. New drugs approved in FY. Japan: Pharmaceuticals and Medical Devices Agency; [cited 2022 Aug 5]. Available from: https://www.pmda.go.jp/files/000246734.pdf
- European Medicines Agency. Scemblix. The Netherlands: European Medicines Agency; [cited 2022 Aug 5]. Available from: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/scemblix
- Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–884. doi: 10.1182/blood-2013-05-501569.
- Cortes JE, Lomaia E, Turkina A, et al. Interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses. J Clin Oncol. 2020;38(15_suppl):7502–7502. doi: 10.1200/JCO.2020.38.15_suppl.7502.
- Molica M, Scalzulli E, Colafigli G, et al. Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia. Ther Adv Hematol. 2019;10:2040620719826444. doi: 10.1177/2040620719826444.
- Réa D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031–2041. doi: 10.1182/blood.2020009984.
- Rea D, Mauro MJ, Hochhaus A, et al. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): week 96 update. J Clin Oncol. 2022;40(16_suppl):7004–7004. doi: 10.1200/JCO.2022.40.16_suppl.7004.
- McGarry LJ, Chen YJ, Divino V, et al. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. Curr Med Res Opin. 2016;32(2):289–299. doi: 10.1185/03007995.2015.1120189.
- Negi H, Agrawal R, Vieira J, et al. PCN231 humanistic and economic burden in patients with chronic myeloid leukemia - a review of the literature. Value Health. 2021;24:s63. doi: 10.1016/j.jval.2021.04.321.
- ClinicalTrials.gov. Study of efficacy of CML-CP patients treated with ABL001 versus bosutinib, previously treated with 2 or more TKIs. USA: National Institutes of Health; [cited 2022 Aug 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT03106779
- Smith BD, Cortes JE, Rea D, et al. CML-353: health care resource utilization (HCRU) with asciminib and bosutinib among patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs): results from the multicenter, open-label phase 3 ASCEMBL trial. Clin Lymphoma Myeloma Leuk 2021;21:s334. doi: 10.1016/S2152-2650(21)01781-X.
- R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2022.
- National Institute for Health and Care Excellence. Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]: committee papers. UK: National Institute for Health and Care Excellence; [cited 2023 Jul 3].